| |
|
|
|
Xtalks, Online
2025-02-27
Cell and gene therapies (CGT) are emerging as novel solutions for disease treatment and prevention.
While promising, CGT involve complex manufacturing processes that demand speed due to the nature of the life-threatening diseases that are being treated. A critical aspect of the manufacturing process is the incorporation of effective, rapid analytical tools for qualifying raw materials and assessing product critical quality attributes (CQAs).
Current analytical tools used in CGT manufacturing for incoming raw materials characterization can be time- and labor-intensive, are often non-standardized and represent a bottleneck in the time to manufacture these critical therapies.
In this webinar, the expert speakers will discuss a multiplexed, microarray-based technology that allows for streamlined quantitative analysis of a wide range of target analytes, including proteins, antibodies and nucleic acids. They will also focus on a case study demonstrating how a multiplexed, microarray-based technology can be used for the quality control of incoming raw materials used in CGT. They will also discuss other potential application areas for which the benefits of a simple, rapid multiplexed platform can provide value to CGT developers and manufacturers.
Register for this webinar today to explore how multiplexed, microarray-based technology is revolutionizing cell and gene therapy manufacturing.
Keywords: Quality Control, Pharmaceutical Manufacturing, Cell Therapy, QC, Cell and Gene Therapies, Cell and Gene Therapy, Cell & Gene Therapy, Cell & Gene Therapies, Quality, CGT
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Randy Lacey, PhD, Field Applications Scientist, InDevR
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-02-27
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|